Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies
European Journal of Haematology · 2026-06 · 116 (6) · 907-914
DOI: 10.1111/ejh.70149 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 05.03.2026. Verfasst von Denise Epple und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine, Technical University of Munich, …. Hauptthemen laut MEDLINE: Lymphocyte Transfusion, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Initiative Krebskranke Kinder e.V., Deutsche Forschungsgemeinschaft, Zukunft Gesundheit e.V..
Abstract (Originalsprache)
Introduction
Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility, safety, and efficacy.
Methods
In total, 10 high‐risk patients received prophylactic DLI following allo‐SCT. Donors were either matched ( n = 5) or haploidentical ( n = 5). CD3+ T‐cell doses of up to 1 × 10 7 cells/kg body weight were administered, in some cases over extended periods exceeding three years.
Results
The treatment was associated with a favorable toxicity profile. In our cohort, 40% of patients developed moderate acute ( n = 2) or chronic ( n = 2) graft‐versus‐host disease (GvHD); no cases of severe or high grade GvHD occurred. Given the high‐risk profile of our cohort, outcomes were encouraging, with relapse‐free survival (RFS) of 70% and overall survival (OS) of 80% at a median follow‐up of 20.5 months. Especially, the two subgroups of patients with acute myeloid leukemia (AML) after relapse and patients who were transplanted in first complete remission (CR1) showed outcomes superior to currently reported data. One AML patient, who had experienced three relapses, received prophylactic DLI after a third allo‐SCT and remains in complete remission (CR), more than 3 years after the last allo‐SCT.
Conclusion
These data suggest that prophylactic DLI may represent a safe and effective treatment option for pediatric patients with hematological malignancies at high risk of posttransplant relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine, Technical University of Munich, Munich, Germany.
- Department of Hematology-Oncology Immunology Infectious Diseases, Klinikum München Schwabing, Munich, Germany.
- Bavarian Stem Cell Bank (Bayerische Stammzellbank), Gauting, Germany.
ORCID-Profile: Denise Epple, Hans-Jochem Kolb
Förderung
- Initiative Krebskranke Kinder e.V.
- Deutsche Forschungsgemeinschaft
- Zukunft Gesundheit e.V.
- Dr. Sepp und Hanne Sturm Memorial Foundation
- Doktor Robert Pfleger-Stiftung
- Wilhelm Sander-Stiftung
Zitieren
APA
Epple, D., Gall, K., Paschke, L., Kolb, H. J., Wawer, A., Knabe, H., von Luettichau, I., Hauer, J., & Thiel, U. (2026). Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies. European Journal of Haematology, 116(6), 907-914. https://doi.org/10.1111/ejh.70149
Vancouver
Epple D, Gall K, Paschke L, Kolb HJ, Wawer A, Knabe H, et al. Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies. European Journal of Haematology. 2026;116(6):907-914. doi:10.1111/ejh.70149
BibTeX
@article{Epple2026,
author = {Epple, Denise and Gall, Katja and Paschke, Luisa and Kolb, Hans-Jochem and Wawer, Angela and Knabe, Hans and von Luettichau, Irene and Hauer, Julia and Thiel, Uwe},
title = {Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies},
journal = {European Journal of Haematology},
year = {2026},
volume = {116},
number = {6},
pages = {907--914},
doi = {10.1111/ejh.70149}
}
EUVIMED